FIZEMEDICAL

FIZE Medical is ushering in a new era of AI-powered fluid management, for smart, personalized, and proactive critically ill patient treatment.

FIZE Medical is pushing forward the boundaries of criticaly ill patients' treatment, envisioning a world where no patient loses their life due to preventable complications from hemodinamic mismanagment.

The FIZE Medical Monitoring and Decision Support Platform:



Fluid Management Optimization Tool - closed loop system monitoring patients Ins and Outs, for personalized, automated fluid management

AI-based predictive algorithms for early detection of Acute Kidney Injury (AKI) and circulatory shock events

Point-of-Care urinalysis, expanding kidney monitoring capabilities and enhancing fast diagnosis of AKI

FIZE kUO, a real-time, digital, highly accurate urine output monitoring device. The device provides insight into kidney status and function, patient hemodynamic status and immediate feedback on patient response to different treatments.

FIZE Medical empowers clinicians with real-time data on patient status, enabling early detection of potential Acute Kidney Injury and shock events, and supporting optimized patient fluid management.

Why fluid managment is essential

Hemodynamics and fluid management are crucial aspects of patient care, neglecting them can lead to dire patient complications, including AKI and circulatory shock. While smart technology exists to manage fluid input data, kidney output remains overlooked.

42%
ICU Patients will acquire AKI[1]

1 in 3
ICU patients will experience circulatory shock[2]

20%
Mortality rate of ICU patients due to AKI[3,4]

38%
Septic shock mortality rate[5]

X10
higher mortality than overall inpatient rate[6]

20%
Hypovolemic shock mortality rate

Our platform not only monitos kidney output but also allow real-time adjustments to fluid input, offering a 360-degree view on patient's hemodynamics status and enabling real-time therapy adjustments for optimized patient outcomes.

Commercially Available

FIZE kUO® Digital Kidney Urine Output Monitoring Platform

FIZE Medical's flagship product, the FIZE kUO platform, brings the precision of digital analytics to ensure that the vital metrics associated with kidney urine output are never overlooked.
By eliminating manual measurement, FIZE kUO is working to improve clinical outcomes by empowering clincians with real time, actionable data at their finger tips. From NICU/PICU to remote ICU servcies, remote monitoring with FIZE kUO is working to improve patient care while increasing ROI overall.

Real-Time Monitoring
Continuous urine output measurement. Digital real-time insights. Immediate feedback on patient status

Unparalleled Accuracy
Microliter resolution capabilities - essential pediatric and neonatal care.

Interconnected Ecosystem
Integrates seamlessly with patient's Electronic Medical Records

Custom Alert
Custom alerts adapted for personalized patient care

Cost Efficiency
Highly affordable business module, encouraging widespread hospital adoption.

Dedicated Pediatric Mode
Only company compatible for pediatric patients. Custom pediatric operating mode.

Ready for immediate deployment
Compatible with existing treatment practices and approved workflows

Partnerships with

PREMIER
contract #KI-NS-019

Kiindo
Contracted Supplier

CLALIT over 100 years
The Best For Your Family

vizient.
Awarded Supplier
contract #MS7284

Clinical Approvals & Market Validation

Patents & Approvals
8 approved patents

Regulatory approval
FDA registered and AMAR approved

Market Validation
FIZE kUO product has been validated in top-tier hospitals in both the U.S. and Israel, with initial sales commencing in these regions.

Commercial Achievements

Key Partnerships
Signed contracts with **Vizient** and **Premier**, the largest purchasing organizations in the U.S., and an exclusive contract with **Clalit**, the largest healthcare provider in Israel.

Market Access
Through ASE Direct, a diversity SDVOSB Supplier, we have formal access to the U.S. VA (Department of Veterans Affairs) and DoD (Department of Defense) markets.

Funding

We have successfully raised **$20 million** to date

Future Product Development

2024
Intra Abdominal Pressure (IAP) measurements, AKI and Shock early prediction algorithm.

2025
Urine Osmolality and Microscipic Hematuria detection, Closed-loop fluid management tool.

Market Opportunity & ROI



Global Market
600k relevant beds, estimating a total market size (including subscription) potential of
$2.3B

Total market
including AI predictive analytics subscription
$3.6 billion

U.S. Market
200k relevant beds with a total market (including subscription) potential of
$1.3B

Cost Savings & ROI

Implementation Cost
FIZE kUO system costs **$1,941** per year per bed.

Current Manual Costs
Manual monitoring costs hospitals approx **$17,500** per year per bed.

Net Savings
Potential cost savings amount to **$15,559** per year per bed.

Leadership

Noam Levine
CTO & Founder
30 years experience in R&D and executive leadership Exists: Redux (acquired by BATM)

Dror Zerem
CEO
20 years of international executive management experience Exists: Ophir Optronics (acquired by Newport), VisionMap (acquired by Rafael.)

Sima Faifman Kuchersky
CCO
10 years of medical device management experience

Eran Blankenstein
CFO
15 years financial experience in multinational/ public companies, including Teva, 888.com, Optimal Plus

Hani Rauch
QA and RA Director
Over 15 years of experience in medical device development & manufacturing and 5 years of cumulative experience in RA and QA.

Yuval Kolodny
VP R&D
Multidisciplinary background in electrical/ computer engineering, applied physics PhD, biotech

FIZEMEDICAL

We invite accredited investors to join us in this exciting journey.
By investing in FIZE, you align yourself with the category leader,
an accomplished team, and a technology that is redefining patient care.

FIZE Medical | info@fizemedical.com | www.fizemedical.com

---

1 | Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73.

2 | Braga D., Barcella M., Herpain A. et al. A longitudinal study highlights shared aspects of the transcriptomic response to cardiogenic and septic shock. Crit Care. 2019;23 414.

3 | Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8:1482-1493 13.

4 | Selby NM, Kolhe NV, McIntyre CW, et al. Defining the cause of death in hospitalised patients with acute kidney injury. PLoS One. 2012;7:e48580

5 |Vincent, JL., Jones, G., David, S. et al. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care 23, 196

6 | Dasta JF, Kane-Gill SL, Durtschi AJ, et al. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant. 2008;23(6):1970- 1974